Rehovot-based central nervous system drug developer NeuroDerm today filed a revised prospectus with the US Security and Exchange Commission (SEC) and announced the value of the IPO on Nasdaq. The company will seek to raise between $60-82 million at a company value of between $236 million and $290 million, after money. Jefferies and Cowen & Company are the joint bookrunners on the deal with Oppenheimer and Roth Capital acting as secondary underwriters. The company will trade under the NDRM ticker. If and when NeuroDerm, and orthopedic drug developer PolyPid Ltd., which set the terms of its Nasdaq IPO last week, complete their IPO, it would mean that a record 10 Israeli biomed companies would have held Nasdaq IPOs in 2014. NeuroDerm has developed a transdermal drug delivery system for the treatment of Parkinson's disease. The company's lead products achieve better results in maintaining uniform levels of the drug in the bloodstream, enabling more effective treatment of the disease with fewer side effects. NeuroDerm's main shareholders include Omrix Biopharmaceuticals founder Robert Taub (28%) who serves as Chairman, Uwe Wascher (25.9%) a former GE senior executive and close friend of Taub and private investor Prof. Shmuel Cabilly (22.2%), while Capital Point Ltd. … Continue reading →

PUBLIC RELEASE DATE: 3-Nov-2014 Contact: Kim Deasy kim.deasy@rhul.ac.uk 01-784-443-967 Royal Holloway, University of London @RoyalHolloway A pioneering piece of technology will allow users to experience the world through the eyes of a person with Young-Onset Parkinson's disease- which could revolutionise the way carers and medical staff treat people with the degenerative condition. Analogue, a theatre company set up by alumni of Royal Holloway, University of London has designed Transports a piece of technology which uses a low cost Raspberry Pi computer system, and allows users to recreate symptoms including dizziness and speech problems, along with wearable technology which creates a 6Hz tremor in the participant's right hand. Young-Onset Parkinson's is a form of the neurological condition which affects people under the age of 50. Symptoms of the disease include tremors, slow movement and dizziness, and with no cure currently available, how care and treatment are managed can make a significant difference to a patient's quality of life. The revolutionary project has been designed in collaboration with neuroscience specialist, Professor Narender Ramnani from the Department of Psychology at Royal Holloway, along with carers, researchers and people with the disease, at Parkinson's UK to ensure it is as effective and realistic as … Continue reading →

By C. Rajan, contributing writer Israeli CNS focused biotech company, NeuroDerm, has just announced positive topline results from the Phase 2 study of its low-dose liquid levodopa/carbidopa combination (ND0612L) in patients with moderate to severe Parkinsons disease. The results showed that continuous, subcutaneous dosing of the drug combination resulted in significant reduction in fluctuations of plasma levodopa concentrations in patients compared to placebo. Patients receiving ND0612L also experienced significant improvement in disease symptoms without an increase in the dyskinesia side effect. The company presented these results at The Michael J. Fox Foundations 2014 Parkinsons Disease Therapeutics Conference in New York this week, along with partial results from its other Phase 2 study of the high-dose form of this drug combination, ND0612H. The Phase 2 study of ND0612H, which began in September, showed that the high-dose form helped maintain consistent levels of plasma levodopa in patients, alone and with oral entacapone, making it an effective day and night treatment option for severe cases of Parkinsons. The company expects to have the final results from this study by the end of this year. The high-dose form is being developed for advanced Parkinsons disease patients, as it has the potential to prevent or … Continue reading →